Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company specializing in the development, production, and commercialization of innovative bioprocessing technologies and systems that enhance the efficiency of biological drug manufacturing. Headquartered in Waltham, Massachusetts, the company operates additional manufacturing facilities in Sweden, Estonia, France, Germany, Ireland, the Netherlands, and the United States.
Repligen is renowned for its high-quality bioprocessing products, which are essential in the production of biological drugs. The company's product portfolio includes Protein A, a critical reagent used in the manufacturing of monoclonal antibody-based therapeutics, and several growth factor products that boost cell culture productivity in biomanufacturing. Additionally, Repligen offers OPUS™ (Open Platform User Specified) single-use chromatography columns, which are pivotal in the biologics purification process.
The company serves a diverse customer base that includes major life sciences and biopharmaceutical companies, as well as contract development and manufacturing organizations (CDMOs) worldwide. Repligen markets its products globally through a direct sales organization in the U.S., Europe, and Asia, complemented by strategic partnerships in select regions. North America remains the primary market, contributing the majority of the company's revenue.
Recent achievements include the acquisition of Metenova AB, a leading innovator in magnetic mixing technologies, to expand its Fluid Management portfolio. Despite challenges in the bioprocessing market, Repligen continues to exhibit resilience with steady revenue growth, particularly in its Analytics and Chromatography franchises.
Financially, Repligen reported second quarter revenues of $159.2 million in 2023 and has adjusted its full-year revenue guidance to a range of $635-$665 million. The company remains optimistic about overcoming current market headwinds, with a growing pipeline of opportunities expected to bolster orders in the fourth quarter.
Overall, Repligen's commitment to bioprocessing technology leadership and continuous innovation positions it as a significant player in the life sciences industry, driving advancements that support the development of life-saving biological drugs.
Repligen Corporation (NASDAQ:RGEN) announced its participation in two prominent investor conferences. The Stifel 2022 Healthcare Conference will take place on November 15-16 in New York, where CFO Jon K. Snodgres will lead a discussion on November 16 at 2:25 p.m. EST. Additionally, the Stephens’ Annual Investment Conference is set for November 15-17 in Nashville, with Snodgres speaking on November 17 at 2:00 p.m. EST. A live webcast will be available on the company’s website and can be replayed for a limited time after the events.
Repligen Corporation (RGEN) reported Q3 2022 revenue of $200.7 million, a 13% year-over-year increase. At constant currency, growth was 19%, with organic growth at 16%. The base business saw a solid 29% revenue growth, expected to reach 33%-34% for the full year. A significant 15-year agreement was established with DRS Daylight Solutions for real-time monitoring technology. Adjusted EPS decreased slightly to $0.77. The company maintains a positive outlook, anticipating overall revenue growth of 19%-20% as reported for 2022.
Repligen Corporation (NASDAQ:RGEN) has renewed its exclusive supply agreement with Purolite to develop affinity ligands for monoclonal antibodies, extending the partnership to 2032. This agreement allows Purolite to access new mAb fragment ligands developed at Avitide and strengthens Repligen's role in the supply of Protein A ligands. The collaboration aligns with Repligen's strategy to enhance market adoption of its Praesto® affinity resin portfolio and secure supply of agarose-based Protein A resins, further establishing their leadership in bioprocessing technologies.
Repligen Corporation (NASDAQ:RGEN) will report its Q3 2022 financial results on November 1, 2022. A press release will be issued before market opening, followed by a conference call at 8:30 a.m. EDT to discuss updates and results for the three and nine month periods ending September 30, 2022.
The call is accessible at (844) 274-3999 (domestic) or (412) 317-5607 (international). A webcast will also be available on the investor relations section of Repligen's website.
Repligen Corporation (NASDAQ:RGEN) has announced a strategic collaboration and exclusive license agreement with DRS Daylight Solutions, lasting 15 years. This partnership aims to enhance the use of mid-infrared (mid-IR) technology in bioprocessing. Repligen will commercialize Daylight's Culpeo® and develop additional products focused on Quantum Cascade Laser mid-IR solutions. This will facilitate real-time monitoring of critical biological manufacturing processes, improving production yields and ensuring product quality.
Repligen Corporation (NASDAQ:RGEN) has announced its upcoming Investor Day 2022 on September 20 in New York City, scheduled from 8:20 to 11:30 a.m. EDT. This live event will feature presentations from the leadership team, followed by a Q&A session. Attendees can register for the in-person event, which is limited to institutional investors and analysts, or access the live webcast on the company's Investor Relations website. A replay will be available post-event.
Repligen Corporation (RGEN) reported record revenue of $207.6 million for Q2 2022, marking a 27% increase year-over-year, with 29% organic growth. The company raised its revenue guidance for the full year 2022 to a range of $790 million to $810 million, up from the previous $770 million to $800 million. Q2 GAAP gross margin was 58.5%, and diluted EPS rose to $0.88, compared to $0.64 in Q2 2021. The strong performance was driven by significant growth in the base business, particularly in Filtration and Chromatography segments.
Repligen Corporation (NASDAQ:RGEN) will report its second quarter 2022 financial results on August 2, 2022, before the market opens. A conference call will follow at 8:30 a.m. EDT to discuss business updates and financial results for the period ending June 30, 2022. Investors can access the call via toll-free numbers for domestic and international callers and will also be available as a webcast on the company's website. The event will be archived for later access.
Repligen Corporation (NASDAQ:RGEN) has appointed Konstantin Konstantinov, Ph.D., to its Board of Directors. With nearly 30 years in the life sciences and bioprocessing industries, Dr. Konstantinov currently serves as Chief Technology Officer at Codiak BioSciences. His experience includes leadership roles at Genzyme and Bayer Healthcare, focusing on the development of biologic drugs and continuous biomanufacturing. The Board expresses optimism about his technical leadership and expertise in bioprocessing, which aligns with Repligen's mission to innovate in the bioprocessing sector.
Repligen Corporation (NASDAQ:RGEN) announced its participation in three upcoming investor conferences. These include the Craig-Hallum 19th Annual Institutional Investor Conference on June 1, the William Blair 42nd Annual Growth Stock Conference in Chicago from June 6-9, where CEO Tony J. Hunt will present on June 7, and the Jefferies Global Healthcare Conference in New York from June 8-10, with CFO Jon K. Snodgres presenting on June 9. Live webcasts of these presentations will be available on Repligen's Investor Relations website.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
What does Repligen Corporation specialize in?
Where is Repligen's headquarters located?
What are some key products offered by Repligen?
Who are Repligen's primary customers?
How does Repligen market its products?
What recent acquisition has Repligen made?
What was Repligen's revenue for the second quarter of 2023?
What is Repligen's revenue guidance for the year 2023?
Which regions contribute the most to Repligen's revenue?
What is Repligen's focus area?
